A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Teprotumumab (Primary)
- Indications Graves ophthalmopathy
- Focus Registrational; Therapeutic Use
- Acronyms OPTIC
- Sponsors Horizon Pharma
- 25 Oct 2017 According to a Horizon Pharma media release, first patient has been enrolled.
- 25 Oct 2017 Status changed from not yet recruiting to recruiting, according to a Horizon Pharma media release.
- 16 May 2017 New trial record